Impact of Hepatitis C Virus Infection on Bone Mineral Density in Renal Transplant Recipients

被引:2
作者
Huang, Wen-Hung [1 ,3 ]
Yu, Mei-Ching [2 ,3 ]
Huang, Jeng-Yi [1 ,3 ]
Lai, Ping-Chin [1 ,3 ]
机构
[1] Chang Gung Mem Hosp, Dept Nephrol, Linkou, Taiwan
[2] Chang Gung Childrens Hosp, Dept Paediat Nephrol, Linkou, Taiwan
[3] Chang Gung Univ, Coll Med, Tao Yuan, Taiwan
关键词
NECROSIS-FACTOR RECEPTOR; VITAMIN-D; LIVER-DISEASE; OSTEOCLAST DIFFERENTIATION; SECONDARY HYPERPARATHYROIDISM; OSTEOPROTEGERIN LIGAND; PARATHYROID-HORMONE; DENDRITIC-CELL; OSTEOPOROSIS; FRACTURES;
D O I
10.1371/journal.pone.0063263
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: The average prevalence of hepatitis C virus (HCV) infection in renal transplant recipients is 10%. Studies of these patients with HCV infection usually focuses on long-term graft survival and patient survival. Studies of the correlation between HCV infection and bone mineral density (BMD) in renal transplant patients are limited. The aim of this study was to investigate whether HCV infection is a risk factor for BMD change during a short follow-up period. Methods: Seventy-six renal transplant recipients underwent 2 separate dual-energy X-ray absorptiometry (DXA) scans during a mean period of 14 months. Fifteen patients were HCV infection. First bone mineral density (BMD) at the lumbar spine, hip, and femoral neck was determined using dual-energy X-ray absorptiometry (DXA) between September 2008 and March 2009. After that, 34 patients took alendronate sodium 70 mg per week. Subgroups risk factors analysis was also performed into with or without alendronate. Immunosuppressive agents, bisphosphonates, patient characteristics, and biochemical factors were analyzed to identify associations with BMD. Results: After 14 months, in 76 patients, BMD of the lumbar spine had significantly increased (from 0.9 g/cm(2) to 0.92 g/cm(2), p < 0.001), whereas BMD of the hip and femoral neck had not. Multiple linear regression analysis showed that HCV infection was negatively associated with BMD change in the lumbar spine (beta: -0.247, 95% CI, -0.035 to -0.002; p = 0.028). Moreover, in subgroup analysis, among 42 patients without alendronate, multiple linear regression analysis showed HCV infection was a risk factor for adverse BMD change of the lumbar spine (beta: -0.371, 95% CI, -0.043 to -0.003; p = 0.023). Conclusion: HCV infection in renal transplant recipients was a negative risk factor for BMD change in the lumbar spine. Moreover, alendronate may be able to reverse the negative effect of HCV infection on bone in renal transplant recipients.
引用
收藏
页数:8
相关论文
共 50 条
[41]   High serum osteoprotegerin and low RANKL in primary biliary cirrhosis [J].
Szalay, F ;
Hegedus, D ;
Lakatos, PL ;
Tornai, I ;
Bajnok, E ;
Dunkel, K ;
Lakatos, P .
JOURNAL OF HEPATOLOGY, 2003, 38 (04) :395-400
[42]   Effect of rapamycin on hepatic osteodystrophy in rats with portasystemnic shunting [J].
van der Merwe, Schalk W. ;
Conradie, Maria M. ;
Bond, Robert ;
Olivier, Brenda J. ;
Fritz, Elongo ;
Nieuwoudt, Martin ;
Delport, Rhena ;
Slavik, Tomas ;
Engelbrecht, Gert ;
Kahn, Del ;
Shephard, Enid G. ;
Kotze, Maritha J. ;
de Villiers, Nico P. ;
Hough, Stephen .
WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (28) :4504-4510
[43]  
von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040297, 10.1016/S0140-6736(07)61602-X]
[44]   Vitamin D, parathyroid hormone levels and bone mineral density in community-dwelling older women:: The Rancho Bernardo Study [J].
von Mühlen, DG ;
Greendale, GA ;
Garland, CF ;
Wan, L ;
Barrett-Connor, E .
OSTEOPOROSIS INTERNATIONAL, 2005, 16 (12) :1721-1726
[45]   Hepatitis C in renal transplantation [J].
Vosnides, GG .
KIDNEY INTERNATIONAL, 1997, 52 (03) :843-861
[46]   Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis-implications for post-transplantation bone disease [J].
Westenfeld, Ralf ;
Schlieper, Georg ;
Woeltje, Michael ;
Gawlik, Alexander ;
Brandenburg, Vincent ;
Rutkowski, Przemyslaw ;
Floege, Juergen ;
Jahnen-Dechent, Willi ;
Ketteler, Markus .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (12) :4115-4123
[47]   TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells [J].
Wong, BR ;
Rho, JR ;
Arron, J ;
Robinson, E ;
Orlinick, J ;
Chao, M ;
Kalachikov, S ;
Cayani, E ;
Bartlett, FS ;
Frankel, WN ;
Lee, SY ;
Choi, YW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (40) :25190-25194
[48]   TRANCE is a TNF family member that regulates dendritic cell and osteoclast function [J].
Wong, BR ;
Josien, R ;
Choi, Y .
JOURNAL OF LEUKOCYTE BIOLOGY, 1999, 65 (06) :715-724
[49]   Osteoclast differentiation factor is a ligand for osteoprotegerin osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL [J].
Yasuda, H ;
Shima, N ;
Nakagawa, N ;
Yamaguchi, K ;
Kinosaki, M ;
Mochizuki, S ;
Tomoyasu, A ;
Yano, K ;
Goto, M ;
Murakami, A ;
Tsuda, E ;
Morinaga, T ;
Higashio, K ;
Udagawa, N ;
Takahashi, N ;
Suda, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (07) :3597-3602
[50]   Increased Rates of Bone Fracture among HIV-Infected Persons in the HIV Outpatient Study (HOPS) Compared with the US General Population, 2000-2006 [J].
Young, Benjamin ;
Dao, Christine N. ;
Buchacz, Kate ;
Baker, Rose ;
Brooks, John T. .
CLINICAL INFECTIOUS DISEASES, 2011, 52 (08) :1061-1068